Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow‐up study

Timp, Jasmijn F.; Lijfering, Willem M.; Flinterman, Linda E.; Vlieg, Astrid van Hylckama; Cessie, Saskia le; Rosendaal, Frits R.; Cannegieter, Suzanne C.

doi:10.1111/jth.13113

Cited by 66 publications

(74 citation statements)

References 38 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As there was a linear association in the decrease of FVIII:C measurement after intake of rivaroxaban/apixaban, FVIII:C might still be a useful predictor while using rivaroxaban or apixaban, however, this requires further validation. VWF:Ag was hardly, if at all, influenced by the treatment and was previously found to have a similar predictive performance to FVIII:C in the MEGA follow‐up study 5. In this study, the risk of a venous thromboembolism recurrence increased stepwise with the highest risk observed for FVIII levels >225 IU/dL: hazard ratio (HR) 4.6 (95% CI 2.9‐7.5), 100 IU/dL as reference.…”

Section: Resultssupporting

confidence: 55%

“…In this study, the risk of a venous thromboembolism recurrence increased stepwise with the highest risk observed for FVIII levels >225 IU/dL: hazard ratio (HR) 4.6 (95% CI 2.9‐7.5), 100 IU/dL as reference. This pattern was similar for VWF:Ag levels, where the observed risk was also highest at levels >225 IU/dL: HR 4.1 (95% CI 2.6‐6.5), <100 IU/dL as reference 5. Thus, VWF:Ag might have a role in future prediction models for venous thromboembolism recurrence for both patients off anticoagulant therapy and patients using a factor Xa inhibitor (at least for rivaroxaban and apixaban).…”

Section: Resultsmentioning

confidence: 62%

“…By preference such a predictor is not influenced by use or type of anticoagulants, optimizing the applicability of the assessment model. Candidate coagulation factors are factor (F)VIII, von Willebrand factor (VWF), and d ‐dimer for which higher levels are associated with increased recurrence risk 3, 4, 5, 6, 7. Preferably, risk assessment and herewith the measurement of these coagulation factors is performed while the patient is still on anticoagulant treatment.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

Scheres

Lijfering

Cheung

et al. 2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

BackgroundPrediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain.ObjectiveTo assess the influence of rivaroxaban and apixaban on several coagulation factor levels.MethodsIn two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individuals immediately before intake of rivaroxaban 15 mg twice daily (n = 6) or apixaban 10 mg twice daily (n = 6) and three hours after the last intake.ResultsOverall, measured levels were lower after rivaroxaban/apixaban intake. The paired mean difference after rivaroxaban intake was −38 IU/dL (95% CI −43; −33) for FVIII:C, −29 U/dL (95% CI −45; −12) for FXI:C, −22 IU/dL (95% CI −43; −1) for FXII:C, −0.11 g/L (95% CI −0.25; 0.03) for fibrinogen, −7 IU/dL (95% CI −18; 3) for VWF:Ag, −27 ng/mL (95% CI −50; −4) for d‐dimer and −0.36 (95% CI −0.57; −0.15) for Ln d‐dimer. After apixaban intake this was −29 IU/dL (95% CI −38; −21) for FVIII:C, −29 IU/dL (95% CI −36; −22) for FXI:C, −19 IU/dL (95% CI −24; −15) for FXII:C, −0.18 g/L (95% CI −0.33; 0.03) for fibrinogen, −52 ng/mL (95% CI −100; −4) for d‐dimer, 0.25 (−0.60; 0.09) for Ln d‐dimer and 1 IU/dL (95% CI −7; 9) for VWF:Ag.Conclusion FVIII:C, FXI:C, FXII:C, and d‐dimer measurements were influenced by rivaroxaban/apixaban intake, while fibrinogen and VWF:Ag were not.

show abstract

Section: Resultssupporting

confidence: 55%

Section: Resultsmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

Scheres

Lijfering

Cheung

et al. 2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Homocysteine and factor VIII were not included in KPCO guidelines and, therefore, were not available routinely for analysis. Hyperhomocysteinemia does not appear to predict VTE recurrence [24]; however, recent research has suggested factor VIII may have a role in future VTE prediction models [25]. We were unable to verify whether family history of VTE involved a first-degree relative in all cases.…”

Section: Discussionmentioning

confidence: 93%

Thrombophilia testing patterns amongst patients with acute venous thromboembolism

Meyer

Witt

Delate

et al. 2015

Thrombosis Research

View full text Add to dashboard Cite

Background Thrombophilia testing has limited value in determining the selection and duration of anticoagulation therapy for venous thromboembolism (VTE), yet is commonly performed. This study describes the patterns and appropriateness of thrombophilia testing in a large cohort of patients with acute VTE. Materials and methods This was a retrospective study of a random sample of patients with a validated diagnosis of acute VTE diagnosed between January 1, 2004 and December 31, 2010. Events were identified from administrative data and verified via manual review. Patients were grouped by thrombophilia testing status and compared on patient characteristics and thrombophilia testing results and appropriateness. Results Of 1,314 patients with validated VTE, 315 (24%) underwent thrombophilia testing, 62 (20%) of whom had ≥ 1 positive test. Tested patients were younger and more likely to have had a family history of VTE. Factor V Leiden (17%) and prothrombin G20210A mutation (4%) were the most commonly detected thrombophilias. Only 31 (10%) of tested patients met eligibility criteria for thrombophilia testing (i.e., at least one strong thrombophilic risk factor present) and were tested at least 90 days following unprovoked index VTE. Conclusions Thrombophilia is commonly evaluated in patients without a clear indication for testing and during times where results may be unreliable. Future studies are needed to assess interventions aimed at reducing inappropriate thrombophilia testing without adversely affecting patient outcomes.

show abstract

“…Elevated plasma FVIII levels enhance venous thrombus formation and propagation [60]. FXI and VWF-mediated FVIII recruitment induce excess thrombin generation may contribute to the growth of a FVIII-driven venous thrombus [61].…”

Section: Vwf In Diseases Beyond Vwd and Ttpmentioning

confidence: 99%

Regulation of VWF expression, and secretion in health and disease

Xiang

Hwa

2016

Current Opinion in Hematology

View full text Add to dashboard Cite

PURPOSE OF REVIEW VWF is a large multi-domain, multimeric glycoprotein that plays an essential role in regulating the balance between blood clotting and bleeding. Aberrant VWF regulation can lead to a spectrum of diseases extending from bleeding disorders (VWD) to aberrant thrombosis (TTP). Understanding the biology of VWF expression and secretion is essential for developing novel targeted therapies for VWF related hemostasis disorders. RECENT FINDINGS A number of recent elegant in vitro and in vivo studies will be highlighted including the discovery of intronic splicing in the VWF gene, miRNA regulated VWF gene expression, and syntaxin binding protein and autophagy mediated VWF secretion. Compared with the already established critical role of VWF in VWD and TTP pathophysiology, additional clinical studies have clarified and reinforced the association of increased plasma levels of VWF with an increased risk of stroke, myocardial infarction, venous thrombosis and diabetic thrombotic complications. Moreover, experimental mouse models of ischaemic stroke and myocardial infarction have further support VWF as a potential therapeutic target. SUMMARY VWF biosynthesis, maturation, and secretion is a complex process, which mandates tight regulation. Significant progress has been made in our understandings of VWF expression and secretion and its association with thrombotic diseases, contributing to the development of novel targeting VWF drugs for prevention and treatment of deficient and enhanced hemostasis.

show abstract

Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow‐up study

Cited by 66 publications

References 38 publications

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

Thrombophilia testing patterns amongst patients with acute venous thromboembolism

Regulation of VWF expression, and secretion in health and disease

Contact Info

Product

Resources

About